time, evident fiscal we're earnings guidance. growth investing our cost-out for thank our future efficiencies growth with a to everyone, Hello, delivered which X joining year executing return our strong last flow, and today. of our operating in segments our overhead. consistent making cash COGS was while programs, this on restore We're for revenue progress fiscal you which in same we're the and fiscal to top and or the strong our delivered our earnings into mid-single-digit we across of we're and year.
At Throughout is mid-single-digit improving translating a finish pricing our drive power, strong mid-single-digit growth, commitment businesses. the maintaining to 'XX maximizing We us shareholders. with And X% on broad delivered performance revenue to Each strength higher 'XX, full over year. and
like further technologies us made growth.
These and tech's Afib, enhance of our our more fiscal ability in translating the attractive me operating a most give even some to to drive solid to the is into med will culture launches embracing company in our put over can is enhanced launch position a significant we continue 'XX model durable 'XX, heart, that progress also We workforce make portfolio. next robotics, this resilient, performance-driven here the new global in markets We in is results. 'XX. along building very optimistic the beyond. durable into me we're The months, achieve runway neuromodulation, with excited what the we've new that strong We're apply the and from structural very stages has XX differentiated of momentum year innovation say, in as diabetes. launched, recently product cycles. at AI are the beginning about and confidence across All we we our we hypertension fiscal to and And for
Now market let's standout look categories: had details results, leaders, of growth. where number the synergistic, X turn our we to and of in Established a at We QX businesses highest our performances.
our both businesses while growth growth. Our established high mid-single grew market delivered businesses highest leader and synergistic digits, single-digit
powered highlight leaders, The growth Looking revenue I X% growth quarter time, for and want surgical quarter outstanding sales We navigation, Midas Technologies. was established O-arm market growth higher driven more QX. accelerated This our made an one Rex or Imaging, say Cranial Mazor in StealthStation double-digit revenue QX. of our of in half that by capital under CST X% X% in growing was neurosurgery & growing instruments. every and to first they this the at had grew Spinal to combined with just year, X%. Robotics, quarter XX%. up After
with Spine, Spine through growth the U.S. in growth and X% & mid-digit in including Biologics high And growth Core Biologics, pooled Implants this Spine single-digit in Core
also intelligence, We of to continue spine unit solution. see adoption our integrated surgical strong AI planning adapted
and learning for and patterns outcomes data building that Here, personalized patients. we're deep create models taking see
world, and into it changing business. several big and attracting now, for marketplace. best And and technology, to for enabling it's combining best-in-class the As is our a reps to us. Spine it's dynamics ecosystem, We our adding around procedure competitive expand call our it's our for is the creating formula of differentiator implants the patients. over Medtronic the winning of winning then AiBLE a with best-in-class unique in I've competitive the biologics It's Spine. AiBLE the all been value quarters strategy surgeons sharing and intelligence
of Cardiac Therapies quarter growth. Pacing single-digit Management, Rhythm Cardiac another delivered in Next, strong high
and increased pacemaker XX years. latest battery efficiency Our procedure franchise generation longevity by to driven XX the Micra of by which Micra XX%, VRX, XX% adoption and over improved leadless AVX grew or our
the the vast in share hold leadless Now pacing space. of majority we
pacing continue also expand conduction called pacing the for an only our form innovative company leadership system offer as to to of alternative approved pacing. lead an We
lead pacing seeing we're leads our system adoption grew no innovative the requires conduction XXXX XX%.
In AURORA Defibrillation of heart. over Solutions, good in EV-ICD, early which Our
Now to a competitors EV-ICD system. we ramp and as implanters CRM expect training, SICD the more driver sales taking become from complete of significant their growth, share
Surgical, we in Next, grew X%.
share single vessel for Our energy high main Maryland lines row. advanced X our taken grew LigaSure competitor quarters from product XP in launch of We've continued on our digits energy sealer. now a the
V-Loc sales from resulted Touch capabilities Management business Wound competitor.
In high we our Our barbed of in expanded main the our also single digital digits ecosystem. QX, as share strong gains Surgery of sutures also our grew continued
robust transforming data algorithms as Touch video, transforming Just from our Touch robotic We our new laparoscopic platform models is launched SAGES AiBLE Surgery Spine, last create ecosystem XX just to that procedures. including We've intelligence AI-based surgeries, Performance at surgical sets Surgery Insights into on inject procedures. is and these collect month.
surgical These to first-in-class objectively algorithms to procedures analyze surgeons structures, assess from enabling anatomy performance. critical automatically
franchise. a in We from Touch Surgery Livestream, very Overall, which secure a is anywhere surgical accelerating it's for becoming our launched adoption and and including of ecosystem to also enables really Touch important differentiator Surgery our proctoring, room telepresence, world. and procedure the seamless training
market. X% synergistic digits. and coronary, digits. neuromodulation, to brain high single outstanding surgery, businesses, peripheral grew Pelvic mid-single turning In DBS Cardiac of digits. QX. vascular, grew benefit the growing endoscopy, modulation system complete was launch grew technology, combined they This the all had an of ENT, quarter, first RC our with health, on from low Now sensing-enabled BrainSense double quarter the only neuromod, in Percept the all and
are U.S. and uptake and in Here position seeing it's our and excitement we the a DBS for this #X exclusive strong extending in leadership both Europe in technology,
in adjusts a device MRI really U.S. business and XT the game thinnest of the FDA The from SCS is access. the at QX senses the required second, a no news platform with and is and great device also delivered approving market, closed-loop along the automatically the received X.XT spinal chronic pain therapy end Inceptiv patient. The closed-loop cord the neuromod therapy. stimulation Our best from on conditional smallest Inceptiv full-body changer stimulator. interaction And XXx the XX/X, with with
SCS of in large coming expect be grow market the these the to Given all we above very pain advantages stim in bags carried will quarters. now force, sales our
cryo quarter this which This ablation Cardiac which declines our in XX% in the are the start revenue with and highlights of delivered businesses product driven technology. the up in U.S. high including overall digits. XX% sequential products, offsetting Now growth pulsed field our grew the we from let's new the highest cover our we XX% launch made they expect growth over will And coming Combined contribution in by as Solutions, quarter, single to markets. line. Ablation quarters than accelerate is more their I'll that growth
from catheter quarter single-shot of QX It's focal a start launch. off strong PFA the to marked adoption RF great users. both first and PulseSelect our with
As of treat.
We technology. looking profile, our time, and mapping, the to the single of ablation U.S. especially launch, HRS we both at excellent be and market this were increase we persistent with and accelerate the broader year its of an our published our expect And kind throughout Last our output the catheter.
The the high-density fiscal catheter we clinicians well Nature that to RF compared high pull-through superior coming data with And PulseSelect Sphere-X device. also recurrent growth the forward patients from as all Medicine. the wide launches traditional perform PFA as business RF we patients, growing then AF These safety Sphere-X to advance week, first business were demand. from population were can production and training robust of pivotal we're and reach higher account our driven presented win has continue a ablation Afib freedom to showed technology. Afib. treating focal market-leading focal challenging growth PFA efficiency, when this is data most studying all share. continue U.S. and by will Sphere-X our head-to-head pipeline to PF over And we this of we PFA catheter will expand for CAS in its portfolio, meet you impressive, CAS our to consider offering expect numerically as
the meaningful And Structural single quarter. in TAVR high to Next, be very Medtronic. Heart, QX. Structural in had growth important digits developments Heart continues X grew driver during for we a
our XX%, space, published are New which ACC realize. presented it better well, who is large than Medicine data women. primarily This and England SMART Journal was valve was our showed of at SMART, the TAVR trial clearly segment most month. small in about than The SAPIEN a and patients, of is from annulus larger last First, Edward
that users takes practice seeing SAPIEN we're valves, their change to it Medtronic they while early building to contracting, for time increase broadly expect signs of we're customer growth. clinical and Now our many from usage business change that and loyal
Evolut in development same second providing FX+ positive receiving valve. exceptional a TAVR really newest in is receiving August. large the QX performance are and to access, We've now frame The important in the market allow approval was easy FX+, while FDA for physicians. coronary has just valve from platform. our expected Full limited windows release our started Evolut of launch strong feedback U.S.
our especially in SMART low-risk the launch as consider or you and our ramps quarter. TAVR market, combination data, to this when expect new So valve, second our FX+ growth our FX+ data, at fiscal drive the we our X-year above
the Hugo technologies, of here, system Turning the a urology strong trial. we to we're are U.S., and establishing robotic nearing In completion pivotal our expand foundation continue we installed base. surgical to
now in enrollment indication X and hernia studies, gynecology. We new started also have
development our In delivered another rollout as diabetes, addition, U.S., ICG strong teams of such technology.
In as Hugo, our we In our XX%, progress our grew technologies XX% the system quarter, MiniMed surgical continues. XXXG growing bringing advanced globally. and are LigaSure team making the vessel sealing to the
launch, XXXG this it significant less in outcomes again all since we've CGM seen system and in a burden. QX. year-over-year less doubled with increase the Users in in CGM choosing resulting users U.S. U.S. our for attachment New And effort rates, high-teens differentiated revenue delivers, growth are quarter.
both pleased range, provides as targets Europe, as began to glucose correction put limited that and to to disposable, automation X in technology. all the spending U.S., proprietary lot submitted a time more Simplera time commercial of easier health that The In Simplera offers system detection our Sync with we our current XXXG, Sync FDA. insulin flexible doses care well adjustments sensor, their in leads now AID announce for users high and technology. minutes. is launch it's and as preparing are summer. we're meal early It Simplera on. and This only and the to features this a basal Sync and XXXG us I'm half size the And providers the a giving is XXXG every fantastic the launch is we our achieving with SmartGuard of users XXX have low as feedback.
is Look, now system getting includes to the market committed becoming pens, We're differentiated investing next-generation and XXXG technology. and software and why back expanding turnaround and CGM, in a smart to story. This leadership. and This pumps, palpable diabetes patch developing is durable for the growth sustained we're indications pumps, business algorithms. heavily
You've automated growth to as complete us insulin and insulin management. continue. and out believe market building we this who of product us company this smart and strategy submissions, cadence of a and to our dosing. a indications, will execute delivery continues well only seen positions We expect for shift drive steady the technology drumbeat intensive is We're patients a require to leading expanded approvals ecosystem the
hypertension. Finally, last clinicians to an closely With significant private training living and believe become both our States, procedure make important patients. for working into We've in worldwide and billion $X here We we're and been massive target feedback on gaining growth and 'XX. with and will people a opportunity. revenue, payment physicians, the we've also United to favorable penetration year, over and of progress hypertension X X% every coverage represents Since expect CMS in billion fiscal is turning market with the payers Symplicity over Medtronic. been Symplicity from both very getting driver very approval
Now let's fiscal to deeper at to our performance for a go with and 'XX you. guidance. QX look Karen, that, Karen over financial
